Logo image of CRON.CA

CRONOS GROUP INC (CRON.CA) Stock Fundamental Analysis

TSX:CRON - Toronto Stock Exchange - CA22717L1013 - Common Stock - Currency: CAD

2.78  +0.05 (+1.83%)

Fundamental Rating

4

Overall CRON gets a fundamental rating of 4 out of 10. We evaluated CRON against 34 industry peers in the Pharmaceuticals industry. While CRON has a great health rating, there are worries on its profitability. CRON is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRON has reported negative net income.
CRON had a positive operating cash flow in the past year.
In the past 5 years CRON reported 4 times negative net income.
In the past 5 years CRON always reported negative operating cash flow.
CRON.CA Yearly Net Income VS EBIT VS OCF VS FCFCRON.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M 1B

1.2 Ratios

The Return On Assets of CRON (-4.01%) is comparable to the rest of the industry.
The Return On Equity of CRON (-4.39%) is better than 69.70% of its industry peers.
Industry RankSector Rank
ROA -4.01%
ROE -4.39%
ROIC N/A
ROA(3y)-16.25%
ROA(5y)0.65%
ROE(3y)-17.03%
ROE(5y)2.26%
ROIC(3y)N/A
ROIC(5y)N/A
CRON.CA Yearly ROA, ROE, ROICCRON.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60

1.3 Margins

CRON's Gross Margin of 14.66% is on the low side compared to the rest of the industry. CRON is outperformed by 69.70% of its industry peers.
In the last couple of years the Gross Margin of CRON has declined.
The Profit Margin and Operating Margin are not available for CRON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-23.24%
CRON.CA Yearly Profit, Operating, Gross MarginsCRON.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K 2K 3K 4K

More info and screens

9

2. Health

2.1 Basic Checks

CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CRON has about the same amount of shares outstanding.
CRON has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRON.CA Yearly Shares OutstandingCRON.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M
CRON.CA Yearly Total Debt VS Total AssetsCRON.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

CRON has an Altman-Z score of 5.71. This indicates that CRON is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 5.71, CRON belongs to the best of the industry, outperforming 96.97% of the companies in the same industry.
CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.71
ROIC/WACCN/A
WACC8.51%
CRON.CA Yearly LT Debt VS Equity VS FCFCRON.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 24.24 indicates that CRON has no problem at all paying its short term obligations.
CRON has a better Current ratio (24.24) than 100.00% of its industry peers.
A Quick Ratio of 23.05 indicates that CRON has no problem at all paying its short term obligations.
CRON's Quick ratio of 23.05 is amongst the best of the industry. CRON outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 24.24
Quick Ratio 23.05
CRON.CA Yearly Current Assets VS Current LiabilitesCRON.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

More info and screens

5

3. Growth

3.1 Past

CRON shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.78%, which is quite impressive.
Looking at the last year, CRON shows a very strong growth in Revenue. The Revenue has grown by 28.05%.
The Revenue has been growing by 48.40% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)77.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%663.28%
Revenue 1Y (TTM)28.05%
Revenue growth 3Y23.14%
Revenue growth 5Y48.4%
Sales Q2Q%38.11%

3.2 Future

Based on estimates for the next years, CRON will show a small growth in Earnings Per Share. The EPS will grow by 6.17% on average per year.
The Revenue is expected to grow by 7.82% on average over the next years.
EPS Next Y7.27%
EPS Next 2Y43.59%
EPS Next 3Y-18.62%
EPS Next 5Y6.17%
Revenue Next Year38.35%
Revenue Next 2Y28%
Revenue Next 3Y13.41%
Revenue Next 5Y7.82%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CRON.CA Yearly Revenue VS EstimatesCRON.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CRON.CA Yearly EPS VS EstimatesCRON.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRON. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 287.84, CRON can be considered very expensive at the moment.
CRON's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CRON is cheaper than 69.70% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.68, CRON is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 287.84
CRON.CA Price Earnings VS Forward Price EarningsCRON.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of CRON indicates a somewhat cheap valuation: CRON is cheaper than 66.67% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 42.52
EV/EBITDA N/A
CRON.CA Per share dataCRON.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A cheap valuation may be justified as CRON's earnings are expected to decrease with -18.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.59%
EPS Next 3Y-18.62%

More info and screens

0

5. Dividend

5.1 Amount

CRON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRONOS GROUP INC

TSX:CRON (2/21/2025, 7:00:00 PM)

2.78

+0.05 (+1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-04 2025-03-04/amc
Inst Owners13.13%
Inst Owner ChangeN/A
Ins Owners5.48%
Ins Owner ChangeN/A
Market Cap1.06B
Analysts74.55
Price Target3.64 (30.94%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-194.12%
Min EPS beat(2)-684.31%
Max EPS beat(2)296.08%
EPS beat(4)2
Avg EPS beat(4)-124.67%
Min EPS beat(4)-684.31%
Max EPS beat(4)296.08%
EPS beat(8)4
Avg EPS beat(8)-80.2%
EPS beat(12)5
Avg EPS beat(12)-76.45%
EPS beat(16)7
Avg EPS beat(16)-67.51%
Revenue beat(2)2
Avg Revenue beat(2)7%
Min Revenue beat(2)4.28%
Max Revenue beat(2)9.73%
Revenue beat(4)3
Avg Revenue beat(4)2.14%
Min Revenue beat(4)-7.38%
Max Revenue beat(4)9.73%
Revenue beat(8)4
Avg Revenue beat(8)-0.46%
Revenue beat(12)6
Avg Revenue beat(12)-2.72%
Revenue beat(16)8
Avg Revenue beat(16)-1.63%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)5.66%
EPS NY rev (3m)7.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)9.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 287.84
P/S 6.73
P/FCF 42.52
P/OCF 26.81
P/B 0.69
P/tB 0.72
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)0.01
Fwd EY0.35%
FCF(TTM)0.07
FCFY2.35%
OCF(TTM)0.1
OCFY3.73%
SpS0.41
BVpS4.01
TBVpS3.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.01%
ROE -4.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.66%
FCFM 15.84%
ROA(3y)-16.25%
ROA(5y)0.65%
ROE(3y)-17.03%
ROE(5y)2.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-23.24%
F-Score6
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 129.19%
Cap/Sales 9.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.24
Quick Ratio 23.05
Altman-Z 5.71
F-Score6
WACC8.51%
ROIC/WACCN/A
Cap/Depr(3y)49.62%
Cap/Depr(5y)329.4%
Cap/Sales(3y)8.38%
Cap/Sales(5y)52.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%663.28%
EPS Next Y7.27%
EPS Next 2Y43.59%
EPS Next 3Y-18.62%
EPS Next 5Y6.17%
Revenue 1Y (TTM)28.05%
Revenue growth 3Y23.14%
Revenue growth 5Y48.4%
Sales Q2Q%38.11%
Revenue Next Year38.35%
Revenue Next 2Y28%
Revenue Next 3Y13.41%
Revenue Next 5Y7.82%
EBIT growth 1Y28.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.67%
EBIT Next 3Y11.15%
EBIT Next 5Y10.5%
FCF growth 1Y116.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y127.8%
OCF growth 3YN/A
OCF growth 5YN/A